ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Drug developers at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
114 drug developers are at ESMO 2026 — 122 presentations on the program and 74 with a booth in the exhibit hall. Most represented: AstraZeneca (4 on the program), GSK (2 on the program), XYone Therapeutics (2 on the program). 77 of them have their own page in this guide. As of Nov 2, 2026.
Tumour type
Top represented
Showing 1–9 of 114 organizations
| Organization | ESMO 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
British pharmaceutical company whose oncology medicines include niraparib, dostarlimab and momelotinib. | Booth Exhibiting at Booth 1023 Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 13:00–14:30 GSK - From Discovery to Impact: ADCs in Endometrial and Ovarian Cancer Care Gynaecological cancers Talk Mon Oct 26 11:05–11:30 Poster Mon Oct 26 12:00–12:45 |
XT XYone Therapeutics Canton, MA | |
Oncology drug developer studying antibody–drug conjugates for cancer treatment. | Poster Fri Oct 23 13:00–15:00 MUC1-C Targeting ADC Exhibits Potent Anti-tumor Activity in KRAS-mutant Gastric Adenocarcinoma Gastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Targeting MUC1 in advanced genitourinary malignancies: Expression landscape, molecular correlates, and preclinical activity of novel antibody-drug conjugates in prostate and bladder cancers Genitourinary cancersBiomarkers & precision oncology Poster Mon Oct 26 12:00–12:45 |
South Korean biotech developing bacteriophage and endolysin-based medicines, including phage-derived candidates for colorectal cancer. | Booth Exhibiting at Booth 1102 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 |
Finnish pharmaceutical company that co-developed the prostate cancer drug darolutamide with Bayer. | Booth Exhibiting at Booth 1047 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 |
Calidi Biotherapeutics San Diego, CA | |
Biotechnology company developing cell and viral therapies for cancer. | Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 |
M mAbxience Madrid, Spain | |
Biotechnology company developing and manufacturing biosimilar medicines. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 LEON study: A PK-driven biosimilarity study of MB11 to nivolumab in advanced melanoma Melanoma & skin cancers |
Healthcare company whose Innovative Medicine business markets oncology drugs including amivantamab, daratumumab and teclistamab. | Booth Exhibiting at Booth 1029 · Johnson & Johnson Innovative Medicine Poster Fri Oct 23 13:00–15:00 Identifying and assessing fit-for-use real-world data sources for homologous recombination repair mutations in prostate cancer: A systematic literature review supplemented by artificial intelligence Genitourinary cancersBiomarkers & precision oncology Satellite Fri Oct 23 18:15–19:45 Satellite Sat Oct 24 14:00–15:30 J&J - Collaborative Precision Care in EGFR-mutated NSCLC. A Multidisciplinary Approach Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 13:00–14:30 Johnson & Johnson - Transforming the Treatment Journey in EGFR- Mutant NSCLC Lung & thoracic cancers |
US biopharmaceutical company whose oncology unit, with cell-therapy arm Kite, markets antibody-drug conjugates and CAR T therapies. | Booth Exhibiting at Booth 8063 · Gilead and Kite Oncology Poster Fri Oct 23 13:00–15:00 Extending RWD–based external control arms from hematologic to lung malignancies for clinical and regulatory decision-making Haematological malignanciesLung & thoracic cancers Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 18:30–20:00 Gilead and Kite Oncology - The ADC Evolution in Breast and Gynaecologic Cancers: Foundation, Advancement, Future Directions Breast cancerGynaecological cancers |
Find buyers from drug developers
Tell us what you sell and we’ll find the people at these drug developers most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ESMO 2026 by
Organization type
Tumour type
Exhibit hall
Everyone
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction